ATSN-301: the dual AAV design and the IND question
Atsena Therapeutics press release, 30 October 2026. Usher syndrome type 1B.
Design
Dual AAV + AAV.SPR
DNA recombination
MYO7A for Usher 1B
NHP retina
Full-length MYO7A
Reached the macula
No foveal detachment
IND path
2027 IND plan
6-month GLP tox
NOAEL at highest dose
Sponsor-reported preclinical findings. They do not establish clinical benefit, and the IND date is a company plan.
Findings as reported by Atsena on 30 October 2026. Preclinical only; the 2027 IND date is a company plan.
Dual AAV meets an IND question.
Six-month GLP tox: NOAEL at top dose.
Atsena reported on 30 October that dual AAV ATSN-301 produced full-length MYO7A in primate retina (company release). A six-month GLP toxicology study set a NOAEL at the highest dose tested, and an IND is planned for 2027.
What was reported
ATSN-301 is described as a gene therapy for Usher syndrome type 1B. It combines Atsena's dual AAV vector, which reconstitutes the gene by DNA recombination, with its laterally spreading AAV.SPR capsid.
The release explains that the MYO7A coding sequence, about 6.7 kb, exceeds the roughly 4.8 kb packaging capacity of a single AAV. Two vectors therefore co-deliver the halves, which are joined by the cell's recombination and splicing machinery.
In cynomolgus macaques, the company reports supraphysiological levels of full-length MYO7A after extrafoveal subretinal injection. It says AAV.SPR spread laterally to the macula and distal retina without surgical detachment of the fovea.
A six-month GLP toxicology study in non-human primates set a no observed adverse effect level at the highest dose evaluated. The company reports minimal truncated protein with no impact on retinal safety, no electroretinogram changes and clean retinal histopathology.
It also reports no treatment-related systemic toxicity, no meaningful immunogenicity and biodistribution confined almost entirely to the injected retina. Atsena plans to submit an IND in 2027. The data were presented at ESGCT and a manuscript is posted to bioRxiv.
What this does and does not show
These are sponsor-reported preclinical findings. They do not show that ATSN-301 improves vision in patients, and a NOAEL in primates is not a clinical safety result.
A NOAEL at the highest dose tested means no adverse effect was seen up to that dose. It does not by itself say how far that dose sits above a clinical dose. The release gives no dose levels, vector genome numbers or animal numbers.
The company states that it is the first to show MYO7A expression in non-human primate retina by immunohistochemistry of retinal cross sections. That is the sponsor's claim. We have read the release, not the bioRxiv manuscript.
What GTC would ask
For developers: how do the study material, dose, biodistribution and toxicology relate to the planned clinical vector and administration approach? Ask which clinical lot and which injection procedure the GLP study represents.
The release highlights DNA recombination and a laterally spreading capsid as design choices. Ask which preclinical result supports each choice, and what bridging work is needed if the clinical design differs from the GLP design.
For investors: the 2027 IND is a company plan. Diligence should focus on the evidence and regulatory work still needed to support it, not on the date.
Practical takeaway
Ask the team to map each clinical design choice to its preclinical evidence and to name the bridging work before anyone fixes an IND timeline. Dual vector programs carry more design choices than single vector programs, so the map is longer.
Related GTC reading
Frequently asked questions
What did Atsena report for ATSN-301?
Atsena reported full-length MYO7A expression in non-human primate retina from a dual AAV vector packaged in the AAV.SPR capsid. It also reported a six-month GLP toxicology study with a NOAEL at the highest dose tested. These are sponsor-reported preclinical findings.
Why does ATSN-301 use two AAV vectors?
The release says the MYO7A coding sequence, about 6.7 kb, exceeds the roughly 4.8 kb packaging capacity of a single AAV vector. Two vectors co-deliver the gene halves, which recombine at the DNA level in the cell.
What does a NOAEL at the highest dose tested mean?
It means no adverse effect was observed up to the highest dose evaluated in that study. It does not establish clinical safety, and it does not by itself define the margin to a clinical dose.
When does Atsena plan to submit an IND for ATSN-301?
Atsena says it plans to submit an IND to the US FDA for ATSN-301 in 2027. That is a company plan, and the release does not describe the remaining work needed to reach it.
Does this show ATSN-301 improves vision?
No. The data are from non-human primates and a toxicology study. The release reports no clinical outcomes, so benefit in patients with Usher syndrome type 1B remains unestablished.
Sources
Join the GTC Expert Network
Independent Experts
Independent experts in cell & gene therapy: share knowledge, help build a report, or contribute quietly. Build authority and get called for paid consulting work. Join free.
Early R&D Experts
Early R&D ExpertsContribute target validation, vector engineering, or transgene design expertise. Get matched to paid consulting work through content you help create.
Join FreeCMC Experts
CMC ExpertsContribute scale-up, tech transfer, or GMP manufacturing expertise. Get matched to paid consulting work through content you help create.
Join FreeRegulatory Affairs Experts
Regulatory Affairs ExpertsContribute IND/BLA strategy or regulatory liaison expertise. Get matched to paid consulting work through content you help create.
Join FreeCommercial & Strategy Experts
Commercial & Strategy ExpertsContribute due diligence, licensing, or market access expertise. Get matched to paid consulting work through content you help create.
Join FreeEnabling Technology Experts
Enabling Technology ExpertsContribute bioprocessing hardware, analytical tooling, or supply-chain expertise. Get matched to paid consulting work through content you help create.
Join FreeAI Transformation Experts
AI Transformation ExpertsContribute agentic workflow, LLM, or AI-driven vector design expertise. Get matched to paid consulting work through content you help create.
Join FreeIndustry Representatives
Industry professionals in cell & gene therapy: de-risk your pipeline with expert input on demand, exactly when your program needs it. Join free.
Drug Developers
Drug DevelopersFounders, CSOs, VPs of R&D
Practical guides spanning vector design through commercialization, plus direct access to the expert network that wrote them.
Join FreeInvestors / VCs
Investors / VCsVC Fund Managers, Family Offices, Angels
Due diligence frameworks and strategic intelligence for evaluating CGT assets, from experts who do this diligence for a living.
Join FreeTechnology Developers
Technology DevelopersFounders, Licensing & Commercial Leads
IP protection and platform strategy guides for enabling technologies, plus the network that built them.
Join FreeCDMOs / CROs
CDMOs / CROsBD, Operations & Technical Leads
Partner selection, vendor evaluation, and operational excellence guides, sourced from the CGT organisations that use them.
Join FreeVendors / Suppliers
Vendors / SuppliersCommercial & Technical Leads
Market intelligence and partnership strategies for supply chain companies serving cell and gene therapy.
Join FreeStrategy Consultants
Strategy ConsultantsConsultants, Market Access Advisors
Spot the problems before they cost your clients - join the network that shapes what GTC covers next.
Join FreeAI Transformation Partners
AI Transformation PartnersAI/ML Consultancies, Digital Transformation Firms
AI education, implementation, and consulting for operational excellence in cell and gene therapy - for companies building or buying AI capability.
Join FreeWhere the analysis comes from. Industry teams get expert input on demand; independent experts build authority and get called for paid consulting work.
See more of our work in Google Search
Google lets you pick the sites you want to see more often in Top Stories. Add Gene Therapy Consultancy to your list, and our daily gene therapy news will show up higher for you.